Skip to main content
Advertisement
Advertisement

AUPH

AUPH logo

Aurinia Pharmaceuticals Inc

16.40
USD
Sponsored
-0.27
-1.62%
Sep 23, 16:00 UTC -4
Closed
exchange

After-Market

16.40

0.00
0.00%

AUPH Earnings Reports

Positive Surprise Ratio

AUPH beat 28 of 43 last estimates.

65%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$85.36M
/
$0.22
Implied change from Q2 26 (Revenue/ EPS)
+2.58%
/
-21.43%
Implied change from Q3 25 (Revenue/ EPS)
+16.19%
/
-4.35%

Aurinia Pharmaceuticals Inc earnings per share and revenue

On Aug 06, 2026, AUPH reported earnings of 0.28 USD per share (EPS) for Q2 26, beating the estimate of 0.24 USD, resulting in a 14.38% surprise. Revenue reached 83.22 million, compared to an expected 80.94 million, with a 2.81% difference. The market reacted with a +6.19% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of 0.22 USD, with revenue projected to reach 85.36 million USD, implying an decrease of -21.43% EPS, and increase of 2.58% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Aurinia Pharmaceuticals Inc reported EPS of $0.28, beating estimates by 14.38%, and revenue of $83.22M, 2.81% above expectations.
The stock price moved up 6.19%, changed from $15.19 before the earnings release to $16.13 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 5 analysts, Aurinia Pharmaceuticals Inc is expected to report EPS of $0.22 and revenue of $85.36M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement